iRhythm Holdings, Inc

iRhythm Holdings, Inc(IRTC)股票分析

$106.050

-1.633 (-1.54%)收盘时

Loading chart…
最高
107.350
开盘
106.570
成交量加权均价
105.97
成交量
482.61K
市值
3.25B
最低
104.520
成交额
51.14M
企业价值/息税折旧摊销前利润(TTM)
37.09

iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in.

AI 分析 of iRhythm Holdings, Inc (IRTC)

持有

iRhythm Technologies Inc (IRTC) is currently priced at $106.70, which is significantly below the analyst price targets of $150 and $196. However, the stock has a low RSI of 42.12, indicating it may not be oversold yet. The company's recent Q2 results showed a revenue of $224.17 million and a narrowed net loss, which is promising, but the stock has seen a year-to-date decline of 39.11%. The main risk is the high forward P/E ratio of 90.91, suggesting that the stock may be overvalued based on future earnings expectations. Therefore, while there are positive catalysts such as revenue guidance increase and acquisition plans, the current market sentiment and performance trends suggest holding rather than buying at this time.

分析师评级(4)

上行空间 +109.34%
买入
3 买入
1 持有
0 卖出
当前: 106.05
最低
205.00
平均
222.00
最高
244.00

Wells Fargo

2026-10-06

目标价

$150

增持

Truist

2026-08-10

目标价

$168

买入

Canaccord

2026-08-07

目标价

$196

买入

Baird

2026-08-07

目标价

$165

跑赢大盘

Stephens

2026-07-22

目标价

$160

增持

估值指标

iRhythm Holdings, Inc(IRTC)当前预期市盈率为 90.91,5 年平均预期市盈率为 -10.56。

预期市盈率

合理
5 年均值 P/E
-10.56
当前P/E
90.91
高估
218.26
低估
-239.38

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
185.91
当前EV/EBITDA
37.09
高估
1089.20
低估
-717.38

预期市销率

低估
5 年均值 P/S
6.09
当前P/S
3.44
高估
8.00
低估
4.18

Alphio AI 对 IRTC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%IRTC

$186.19

情景价格

基

基准

基准 · 50%IRTC

$184.84

情景价格

悲

悲观

悲观 · 25%IRTC

$178.24

情景价格

持有 IRTC 的大户

B

Braidwell LP

+ 持有IRTC

+13.80%

3个月收益率

E

Eventide Asset Management, LLC

+ 持有IRTC

-6.19%

3个月收益率

R

RTW Investments, LP

+ 持有IRTC

-11.48%

3个月收益率

R

Rock Springs Capital Management LP

+ 持有IRTC

-11.63%

3个月收益率

P

Perceptive Advisors LLC

+ 持有IRTC

-17.58%

3个月收益率

事件时间线

2026-10-02 (ET)

17:00:00

iRhythm Updates on Cybersecurity Incident Notification

2026-08-06 (ET)

16:30:00

iRhythm Expects 2026 Revenue of $880M to $890M

16:30:00

iRhythm Reports Q2 Revenue of $224.17M, Exceeds Expectations

16:30:00

iRhythm Acquires Vital Connect for $287.5 Million

资讯

IRTC 常见问题 —— 由 Alphio AI 解答

iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

iRhythm Technologies Inc (IRTC) is currently priced at $106.70, which is significantly below the analyst price targets of $150 and $196. However, the stock has a low RSI of 42.12, indicating it may not be oversold yet. The company's recent Q2 results showed a revenue of $224.17 million and a narrowed net loss, which is promising, but the stock has seen a year-to-date decline of 39.11%. The main risk is the high forward P/E ratio of 90.91, suggesting that the stock may be overvalued based on future earnings expectations. Therefore, while there are positive catalysts such as revenue guidance increase and acquisition plans, the current market sentiment and performance trends suggest holding rather than buying at this time.

4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易